Bone marrow transplantation for acquired severe aplastic anemia

Area of Science:

• Hematology
• Transplantation Medicine
• Immunology

Background:

• Acquired severe aplastic anemia (SAA) is a life-threatening condition requiring effective treatment.
• Hematopoietic stem cell transplantation (HSCT) is a primary curative option for SAA.
• Limited availability of HLA-identical sibling donors necessitates exploration of alternative donor sources.

Purpose of the Study:

• To review current and emerging stem cell transplant strategies for acquired severe aplastic anemia (SAA).
• To evaluate the efficacy and outcomes of various donor types and transplant protocols.
• To provide an overview of recent advancements in SAA transplant management.

Main Methods:

• Review of recent clinical data and literature on HSCT for SAA.
• Analysis of outcomes based on donor type (unrelated, cord blood, haploidentical).
• Discussion of conditioning regimens and graft-versus-host disease (GVHD) prophylaxis.

Main Results:

• Unrelated donor HSCT outcomes are approaching those of HLA-identical sibling transplants.
• Advances in stem cell sources, conditioning, and GVHD prophylaxis improve SAA transplant success.
• Cord blood and haploidentical mismatched family donors represent viable alternative options.

Conclusions:

• Stem cell transplantation offers effective treatment for acquired severe aplastic anemia.
• The expanding use of unrelated donors and other alternative sources significantly broadens transplant eligibility.
• Ongoing research in HSCT protocols continues to improve outcomes for SAA patients.